Animal study · mice
SS-31 eased LPS-induced learning and memory problems in mice
Checked against the paper Animal studyPublished by PepVault
The takeaway
This mouse study adds early lab evidence that SS-31 protected memory and brain mitochondria under inflammatory stress, but it has not been shown in humans.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2019
- Journal
- J Neuroinflammation
What they tested
The team tested whether elamipretide (SS-31) could protect mice from the learning and memory problems, inflammation and oxidative stress (cell damage from reactive molecules) that follow lipopolysaccharide (LPS) treatment.
How the study was done
A lab study in mice given LPS, with or without elamipretide. Learning and memory were tested with a maze test (MWM) and a contextual fear conditioning test, and the hippocampus, a brain area tied to memory, was examined for mitochondrial function, oxidative stress, inflammation, cell death and dendritic spines (tiny bumps on nerve cell branches).

What they found
In mice, LPS led to poor mitochondrial function, oxidative stress, inflammation, nerve cell death and fewer dendritic spines in the hippocampus, along with worse scores on both memory tests. Mice that also got elamipretide did significantly better on these learning and memory tests. Elamipretide also protected mitochondrial function, reduced oxidative stress, supported BDNF (brain-derived neurotrophic factor) signaling, restored key synaptic proteins and increased the structural complexity of synapses, the connection points between nerve cells.
What it doesn’t show
This was a study in mice using one LPS model, so it does not show the same effect in people. The authors' link to memory problems after surgery is an idea for future testing, not something this study measured in patients.
The paper
Zhao et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.